Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Neopenda is a medical device startup creating solutions that give patients in low-...
Neopenda is a medical device startup creating s...
RTI Surgical Holdings, Inc. is a leading global surgical implant company providing...
RTI Surgical Holdings, Inc. is a leading global...
As a leading genome editing company, Editas Medicine is focused on translating the...
As a leading genome editing company, Editas Med...
Advaxis was founded on the vision that no one should suffer from the burdens of ca...
Advaxis was founded on the vision that no one s...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-stage biotechnology company focused ...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-s...
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company fo...
Amarin Corporation plc. is a rapidly growing, i...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
Join the National Investor Network and get the latest information with your interests in mind.